<DOC>
	<DOCNO>NCT00898690</DOCNO>
	<brief_summary>RATIONALE : DNA analysis tumor tissue may help doctor predict patient receive paclitaxel respond treatment . PURPOSE : This laboratory study evaluate gene expression predict response paclitaxel patient breast cancer .</brief_summary>
	<brief_title>Gene Expression Predicting Response Paclitaxel Patients With Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine whether loss function FEZ1/LZTS1 gene predictor response patient breast cancer treat paclitaxel . OUTLINE : This single-blind study . Tumor tissue analyze FEZ1/LZTS1 gene expression immunohistochemistry use antibody gene . Tumor expression gene characterize immunohistochemistry score intensity staining , percent cell staining , stain index . Tumor tissue also analyze FEZ1/LZTS1 gene disruption reverse transcriptase-polymerase chain reaction direct sequencing . PROJECTED ACCRUAL : Approximately 120 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis breast cancer Measurable disease Metastatic disease identify image study OR primary disease site treat neoadjuvant protocol Lesions â‰¥ 10 mm spiral CT scan Tumor tissue primary metastatic site available analysis immunohistochemistry Previously treat OR plan undergo treatment paclitaxel* NOTE : *Concurrent enrollment ECOG2100 allow Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Not specify PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2006</verification_date>
	<keyword>stage I breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>